Vascular complications of diabetes pose a severe threat to human health. Prevention and
treatment protocols based on a single vascular complication are no longer suitable for the …

Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP1)
exhibit incretin activity, meaning that they potentiate glucose-dependent insulin secretion …

The SELECT trial previously reported a 20% reduction in major adverse cardiovascular
events with semaglutide (n= 8,803) versus placebo (n= 8,801) in patients with …

Background Chronic kidney disease (CKD) is a common complication of type 2 diabetes
(T2D). Glucagon-like peptide-1 receptor agonists (GLP-1RAs) improve glycaemic control …

Background In the SURPASS-4 trial, the dual GIP and GLP-1 receptor agonist tirzepatide
reduced HbA 1c concentrations, bodyweight, and blood pressure more than titrated daily …

Background GLP-1 receptor agonists reduce major adverse cardiovascular events (MACE)
in patients with type 2 diabetes. However, uncertainty regarding kidney outcomes persists …

To date, non-alcoholic fatty liver disease (NAFLD) is the most frequent liver disease,
affecting up to 70% of patients with diabetes. Currently, there are no specific drugs available …

Background GLP-1 receptor agonists (GLP-1 RAs) with exenatide bid first approved to treat
type 2 diabetes in 2005 have been further developed to yield effective compounds …

Background Four glucagon-like peptide-1 (GLP-1) receptor agonists that are structurally
similar to human GLP-1 have been shown to reduce the risk of adverse cardiovascular …

In Japan, a super-aged society, deaths from atherosclerotic cardiovascular disease
(ASCVD), especially cardiac diseases including coronary artery disease (CAD) such as …